拜卡莱因通过抑制JAK2/STAT3通路增强结肠直肠癌中的辐射敏感性
Qingqing Yu1, Rongjun Tang2, Weixing Mo3
1Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China.
Chemical biology & drug design
|August 16, 2024
概括
拜卡莱因 (BE) 通过抑制JAK2/STAT3通路来增强结直肠癌 (CRC) 的辐射敏感性. 这项研究表明,BE增加了亡和瘤抑制,为CRC放射治疗提供了潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 抗辐射是结直肠癌 (CRC) 治疗的一个重大挑战.
- 来自Scutellaria baicalensis的化合物Baicalein (BE) 显示出抗CRC的潜力,但其对辐射敏感性的影响尚不清楚.
- 了解克服放射电阻的机制对于改善CRC治疗结果至关重要.
研究的目的:
- 评估 Baicalein (BE) 在结肠直肠癌 (CRC) 中的放射敏感化作用.
- 在CRC放射治疗中阐明BE介导放射敏感化的潜在分子机制.
- 研究JAK2/STAT3通路对BE对CRC辐射敏感性影响的作用.
主要方法:
- 建立了体外抗辐射CRC细胞模型 (CT26-R) 和体内CRC小鼠模型.
- 通过殖民地形成试验评估细胞增殖和使用TUNEL试验评估细胞亡.
- 测量了蛋白质表达水平 (p-STAT3,JAK2,PD-L1,SOCS3) 使用西式涂抹,通过pcDNA-JAK2转染通过JAK2调制.
主要成果:
- 拜卡莱因 (BE) 在体外和体外结直肠癌 (CRC) 模型中显著增强了辐射敏感性.
- BE治疗导致瘤组织中亡的增加.
- BE降低了p-STAT3,JAK2和PD-L1表达的调节,同时提高了SOCS3的调节;这些效应被pcDNA-JAK2逆转.
结论:
- 拜卡莱因 (BE) 有效地增强了结肠直肠癌 (CRC) 的辐射敏感性.
- BE通过抑制JAK2/STAT3信号通路来发挥其辐射敏感作用.
- BE代表了一种有前途的治疗剂,可以提高CRC放射治疗的疗效.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.7K
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.5K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
